Xiamen Innovax Biotech presents HPV vaccine research at IPVS 2026

Xiamen Innovax Biotech (IX) participated in the 38th Annual International Papillomavirus Society Conference (IPVS 2026), held in Athens, Greece, from October 22 to 25. The firm utilized the platform to engage with global health experts on the challenges and progress of HPV prevention initiatives.

Company representatives focused on presenting clinical findings related to the efficacy of its HPV vaccine, Cecolin, and explored collaborative strategies to improve immunization accessibility. The dialogue emphasized the role of international partnerships in scaling up public health interventions against cervical cancer.

This participation reflects Innovax’s ongoing efforts to engage with the global scientific community and integrate its products into broader international health programs. The event concluded with a renewed focus on evidence-based approaches to achieving HPV-related disease elimination targets.